Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 31 of 31 matching drugs for GNRHR — including drugs targeting any of its 18 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
pd0332991, anastrozole, goserelin, surgery (standard of care), tumor biopsy GNRHR Direct 1
abarelix GNRHR Direct yes 0
buserelin GNRHR Direct yes 0
cetrorelix acetate GNRHR Direct yes 0
degarelix GNRHR Direct yes 0
degarelix acetate GNRHR Direct yes 0
elagolix GNRHR Direct yes 0
elagolix sodium GNRHR Direct yes 0
gonadorelin GNRHR Direct yes 0
gonadorelin acetate GNRHR Direct yes 0
gonadorelin hydrochloride GNRHR Direct yes 0
goserelin GNRHR Direct yes 0
goserelin acetate GNRHR Direct yes 0
histrelin GNRHR Direct yes 0
histrelin acetate GNRHR Direct yes 0
leuprolide GNRHR Direct yes 0
leuprolide acetate GNRHR Direct yes 0
nafarelin GNRHR Direct yes 0
nafarelin acetate GNRHR Direct yes 0
relugolix GNRHR Direct yes 0
triptorelin GNRHR Direct yes 0
triptorelin pamoate GNRHR Direct yes 0
unnamed compound GNRHR Direct yes 0
digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin ATP1A1 SSL via ATP1A1 1
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
acetyldigitoxin ATP1A1 SSL via ATP1A1 yes 0
ataluren RPL22 SSL via RPL22 yes 0
deslanoside ATP1A1 SSL via ATP1A1 yes 0
digitoxin ATP1A1 SSL via ATP1A1 yes 0
digoxin ATP1A1 SSL via ATP1A1 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.